{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:15:07Z","timestamp":1788048907867,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001840","name":"RANN\u00cdS","doi-asserted-by":"publisher","award":["14193\\u2013051"],"award-info":[{"award-number":["14193\\u2013051"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001840","name":"RANN\u00cdS","doi-asserted-by":"publisher","award":["152077\\u2013051"],"award-info":[{"award-number":["152077\\u2013051"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canep.2026.103204","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:14:44Z","timestamp":1786958084000},"page":"103204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["TP53 mutations predict poor breast cancer\u2013specific survival in ER-positive breast cancer patients"],"prefix":"10.1016","volume":"104","author":[{"given":"S.","family":"Ragnarsdottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Frick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.A.","family":"Stefansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tryggvadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Aspelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bjarnadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vidarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7471","key":"10.1016\/j.canep.2026.103204_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.canep.2026.103204_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the Cellular Gatekeeper for Growth and Division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.canep.2026.103204_bib3","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: An insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.canep.2026.103204_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.canep.2026.103204_bib5","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.celrep.2019.08.061","article-title":"Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell. Rep."},{"issue":"1","key":"10.1016\/j.canep.2026.103204_bib6","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"10","key":"10.1016\/j.canep.2026.103204_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.canep.2026.103204_bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.canep.2026.103204_bib9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12964-024-01863-9","article-title":"Targeting mutant p53: a key player in breast cancer pathogenesis and beyond","volume":"22","author":"Qayoom","year":"2024","journal-title":"Cell. Commun. Signal."},{"issue":"2","key":"10.1016\/j.canep.2026.103204_bib10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.breast.2013.07.005","article-title":"p53 in breast cancer subtypes and new insights into response to chemotherapy","volume":"22","author":"Bertheau","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.canep.2026.103204_bib11","article-title":"Survival outcomes by TP53 mutation status in metastatic breast cancer","volume":"2018","author":"Meric-Bernstam","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"13","key":"10.1016\/j.canep.2026.103204_bib12","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1158\/1078-0432.CCR-13-2943","article-title":"TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance","volume":"20","author":"Silwal-Pandit","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.canep.2026.103204_bib13","first-page":"1637","article-title":"Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor","volume":"53","author":"Thorlacius","year":"1993","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canep.2026.103204_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1699-0463.1997.tb00550.x","article-title":"Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis","volume":"105","author":"Valgardsdottir","year":"1997","journal-title":"Apmis"},{"issue":"7418","key":"10.1016\/j.canep.2026.103204_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours.","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"7605","key":"10.1016\/j.canep.2026.103204_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"issue":"7403","key":"10.1016\/j.canep.2026.103204_bib17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canep.2026.103204_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.canep.2026.103204_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41523-022-00437-7","article-title":"Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases","volume":"8","author":"Hurson","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"7","key":"10.1016\/j.canep.2026.103204_bib20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3109\/0284186X.2012.698751","article-title":"Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness","volume":"51","author":"Sigurdardottir","year":"2012","journal-title":"Acta Oncol."},{"issue":"5","key":"10.1016\/j.canep.2026.103204_bib21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4161\/epi.6.5.15667","article-title":"CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer","volume":"6","author":"Stefansson","year":"2011","journal-title":"Epigenetics"},{"issue":"2","key":"10.1016\/j.canep.2026.103204_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nmeth.1419","article-title":"Target-enrichment strategies for next-generation sequencing","volume":"7","author":"Mamanova","year":"2010","journal-title":"Nat. Methods"},{"issue":"7356","key":"10.1016\/j.canep.2026.103204_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nature10242","article-title":"An integrated semiconductor device enabling non-optical genome sequencing","volume":"475","author":"Rothberg","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canep.2026.103204_bib24","first-page":"859","article-title":"BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability","volume":"58","author":"Gretarsdottir","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.canep.2026.103204_bib25","article-title":"Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canep.2026.103204_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-019-0117-7","article-title":"Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression","volume":"5","author":"Abubakar","year":"2019","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.canep.2026.103204_bib27","first-page":"34","article-title":"TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)","volume":"16","author":"Huszno","year":"2018","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.canep.2026.103204_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trecan.2020.01.007","article-title":"TP53 mutations and outcomes in breast cancer: reading beyond the headlines","volume":"6","author":"Shahbandi","year":"2020","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.canep.2026.103204_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/modpathol.2013.153","article-title":"Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information","volume":"27","author":"Feeley","year":"2014","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.canep.2026.103204_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100100","article-title":"p53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance","volume":"36","author":"Mueller","year":"2023","journal-title":"Mod. Pathol."},{"issue":"18","key":"10.1016\/j.canep.2026.103204_bib31","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1101\/gad.1339905","article-title":"p53 isoforms can regulate p53 transcriptional activity","volume":"19","author":"Bourdon","year":"2005","journal-title":"Genes. Dev."},{"issue":"6","key":"10.1016\/j.canep.2026.103204_bib32","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum. Mutat."},{"issue":"9132","key":"10.1016\/j.canep.2026.103204_bib33","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials.","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.canep.2026.103204_bib34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canep.2026.103204_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13058-018-1044-5","article-title":"Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment","volume":"20","author":"Ungerleider","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"23","key":"10.1016\/j.canep.2026.103204_bib36","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1002\/cam4.4376","article-title":"TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer","volume":"10","author":"Grote","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.canep.2026.103204_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"issue":"11","key":"10.1016\/j.canep.2026.103204_bib38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/oxfordjournals.aje.a009758","article-title":"Confounding by indication: an example of variation in the use of epidemiologic terminology","volume":"149","author":"Salas","year":"1999","journal-title":"Am. J. Epidemiol."},{"issue":"20","key":"10.1016\/j.canep.2026.103204_bib39","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canep.2026.103204_bib40","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"18","key":"10.1016\/j.canep.2026.103204_bib41","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.canep.2026.103204_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting CDK4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp. Mol. Med."},{"issue":"11","key":"10.1016\/j.canep.2026.103204_bib43","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","article-title":"Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion","volume":"42","author":"Kudo","year":"2024","journal-title":"Cancer Cell."},{"issue":"3","key":"10.1016\/j.canep.2026.103204_bib44","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canep.2026.103204_bib45","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fphar.2024.1474337","article-title":"Advancing cancer therapy: new frontiers in targeting DNA damage response","volume":"15","author":"Qian","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.canep.2026.103204_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00432-023-05527-y","article-title":"An update of predictive biomarkers related to WEE1 inhibition in cancer therapy","volume":"150","author":"Wang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126002201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126002201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:19:41Z","timestamp":1788045581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782126002201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S1877782126002201"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2026.103204","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 mutations predict poor breast cancer\u2013specific survival in ER-positive breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2026.103204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103204"}}